ImmunoPrecise Antibodies Price to Free Cash Flow Ratio 2022-2025 | IPA

ImmunoPrecise Antibodies price to free cash flow ratio from 2022 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Veeva Systems (VEEV)$35.1B
Tempus AI (TEM)$7B
Hims & Hers Health (HIMS)$6B
Inspire Medical Systems (INSP)$4.5B
IRhythm Technologies (IRTC)$3.2B
Privia Health (PRVA)$2.9B
Schrodinger (SDGR)$1.9B
Clover Health Investments (CLOV)$1.8B
Enovis (ENOV)$1.8B
Omnicell (OMCL)$1.4B
Phreesia (PHR)$1.4B
Azenta (AZTA)$1.2B
10x Genomics (TXG)$918M
Butterfly Network (BFLY)$568M
Fulgent Genetics (FLGT)$551M
Talkspace (TALK)$450M
Veradigm (MDRX)$449M
Standard BioTools (LAB)$440M
TruBridge (TBRG)$363M
Claritev (CTEV)$325M
Health Catalyst (HCAT)$270M
Nyxoah SA (NYXH)$206M
SOPHiA GENETICS SA (SOPH)$189M
Pulmonx (LUNG)$182M
American Well (AMWL)$109M
EUDA Health Holdings (EUDA)$100M
Retrieve Medical Holdings (RMHI)$82M
MDxHealth SA (MDXH)$76M
P3 Health Partners (PIII)$66M
111 (YI)$64M